2021
DOI: 10.1016/j.japh.2020.10.010
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacist counseling when dispensing naloxone by standing order: A secret shopper study of 4 chain pharmacies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 19 publications
(16 citation statements)
references
References 31 publications
0
16
0
Order By: Relevance
“…Trained researchers, including the authors and student researchers, used novel “secret shopper” methodology to call all independent pharmacies in Georgia posing as unidentified customers inquiring about the availability of naloxone at that pharmacy. This approach has been previously used in other studies accessing the availability of naloxone at pharmacies [ 31 , 38 ]. One form of naloxone, a nasal spray, is FDA-approved and can be easily administered.…”
Section: Methodsmentioning
confidence: 99%
“…Trained researchers, including the authors and student researchers, used novel “secret shopper” methodology to call all independent pharmacies in Georgia posing as unidentified customers inquiring about the availability of naloxone at that pharmacy. This approach has been previously used in other studies accessing the availability of naloxone at pharmacies [ 31 , 38 ]. One form of naloxone, a nasal spray, is FDA-approved and can be easily administered.…”
Section: Methodsmentioning
confidence: 99%
“…Unfortunately, the preponderance of evidence regarding pharmacists’ current practices related to naloxone dispensing indicates this level of clinical service is increasingly rare in US pharmacies, and that in some cases, a pharmacist may be more likely to hinder naloxone access than to facilitate it. 41 , 56 Furthermore, the concern raised by SPPCP could be similarly applied to nearly any OTC medication, including many which possess risks for harm from improper use that exceed that of naloxone. In fact, over a million doses of naloxone are distributed annually from non-pharmacy OEND programs, with no evidence of harmful effects.…”
Section: Potential Benefits and Risks Of Otc Transitionmentioning
confidence: 99%
“… 59 , 78 However, studies continue to document gaps in both pharmacist-reported knowledge regarding naloxone and its actual practice behaviors related to its dispensing, indicating that these educational efforts must remain a high priority. 51 , 56 , 59 , 78 , 79 It is possible that converting naloxone to OTC status could remove a powerful incentive for pharmacists to seek, and colleges of pharmacy to provide, opioid-related education. However, this need not and should not be the case, especially since we envision that some formulations would likely remain prescription-only even if more user-friendly versions are moved OTC.…”
Section: Potential Benefits and Risks Of Otc Transitionmentioning
confidence: 99%
“… 4–6 Furthermore, pharmacists rarely assess the need for, or counsel on the benefits of, OUD treatment when dispensing naloxone, and often report feeling unprepared to do so. 7 , 8 …”
Section: Dear Editormentioning
confidence: 99%
“…4-6 Furthermore, pharmacists rarely assess the need for, or counsel on the benefits of, OUD treatment when dispensing naloxone, and often report feeling unprepared to do so. 7,8 Despite continuing legal and regulatory barriers associated with naloxone's status as a prescription-only medication, many people currently obtain naloxone without ever meeting a medical provider. In fact, harm reduction organizations were for many years the dominant source of take-home naloxone.…”
mentioning
confidence: 99%